SCHEMBL17438024

SCHEMBL17438024

CCn1c(C)c(C(=O)NC/C=C/C(=O)OC)c2cc(OC)ccc21

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.67
KMT2A Q03164 2/20 0.67
NPC1 O15118 1/20 0.67
RAB9A P51151 1/20 0.67
KDM4E B2RXH2 4/20 0.61
HSD17B10 Q99714 1/20 0.49
MAPT P10636 5/20 0.46
TP53 P04637 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
POLB P06746 2/20 0.44
LMNA P02545 2/20 0.44
PKM P14618 2/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44
PTGER4 P35408 1/20 0.44
PLA2G2A P14555 1/20 0.44
ALDH1A1 P00352 2/20 0.43
TSHR P16473 1/20 0.43
ATM Q13315 1/20 0.42
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17438153 0.92 MEN1 (0.56) MEN1KMT2ANPC1RAB9AKDM4E
SCHEMBL17438037 0.87 MAPT (0.57) MEN1KMT2ANPC1RAB9AKDM4E
SCHEMBL17447397 0.87 PLA2G2A (0.62) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL17445858 0.87 KMT2A (0.49) MEN1KMT2ANPC1RAB9AKDM4E
SCHEMBL17438065 0.83 NPC1 (0.45) MEN1KMT2ANPC1RAB9AKDM4E
SCHEMBL17447380 0.82 MAPT (0.56) MEN1KMT2ANPC1RAB9AKDM4E
SCHEMBL17438027 0.82 MEN1 (0.66) MEN1KMT2ANPC1RAB9AKDM4E
SCHEMBL17447385 0.81 GAA (0.44) MEN1KMT2ANPC1RAB9AKDM4E
SCHEMBL17438101 0.81 GAA (0.46) MEN1KMT2ANPC1RAB9AKDM4E
SCHEMBL17438095 0.80 MAPT (0.56) MEN1KMT2ANPC1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10273208-B2 Screening methods for the binding affinity of chemical entities to biological molecules and NEDD4-1 inhibitors identified by the screening methods NORTHWESTERN UNIVERSITY (US) 2019-04-30 US disclosed
US-10273208-B2 Screening methods for the binding affinity of chemical entities to biological molecules and NEDD4-1 inhibitors identified by the screening methods NORTHWESTERN UNIVERSITY (US) 2019-04-30 US disclosed
US-20170152228-A1 SCREENING METHODS FOR THE BINDING AFFINITY OF CHEMICAL ENTITIES TO BIOLOGICAL MOLECULES AND NEDD4-1 INHIBITORS IDENTIFIED BY THE SCREENING METHODS NORTHWESTERN UNIVERSITY (US) 2017-06-01 US disclosed
US-20170152228-A1 SCREENING METHODS FOR THE BINDING AFFINITY OF CHEMICAL ENTITIES TO BIOLOGICAL MOLECULES AND NEDD4-1 INHIBITORS IDENTIFIED BY THE SCREENING METHODS NORTHWESTERN UNIVERSITY (US) 2017-06-01 US disclosed
US-9586890-B2 Screening methods for the binding affinity of chemical entities to biological molecules and NEDD4-1 inhibitors identified by the screening methods NORTHWESTERN UNIVERSITY (US) 2017-03-07 US disclosed
US-9586890-B2 Screening methods for the binding affinity of chemical entities to biological molecules and NEDD4-1 inhibitors identified by the screening methods NORTHWESTERN UNIVERSITY (US) 2017-03-07 US disclosed
US-20160016893-A1 SCREENING METHODS FOR THE BINDING AFFINITY OF CHEMICAL ENTITIES TO BIOLOGICAL MOLECULES AND NEDD4-1 INHIBITORS IDENTIFIED BY THE SCREENING METHODS NORTHWESTERN UNIVERSITY (US) 2016-01-21 US disclosed
US-20160016893-A1 SCREENING METHODS FOR THE BINDING AFFINITY OF CHEMICAL ENTITIES TO BIOLOGICAL MOLECULES AND NEDD4-1 INHIBITORS IDENTIFIED BY THE SCREENING METHODS NORTHWESTERN UNIVERSITY (US) 2016-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170152228-A1 SCREENING METHODS FOR THE BINDING AFFINITY OF CHEMICAL ENTITIES TO BIOLOGICAL MOLECULES AND NEDD4-1 INHIBITORS IDENTIFIED BY THE SCREENING METHODS NEDD4, STUB1, CUL1 MEN1 2112/4885KMT2A 2599/4885NPC1 1703/4885
US-20160016893-A1 SCREENING METHODS FOR THE BINDING AFFINITY OF CHEMICAL ENTITIES TO BIOLOGICAL MOLECULES AND NEDD4-1 INHIBITORS IDENTIFIED BY THE SCREENING METHODS NEDD4, STUB1, UBQLN1 MEN1 2241/4885KMT2A 3105/4885NPC1 376/4885
US-10273208-B2 Screening methods for the binding affinity of chemical entities to biological molecules and NEDD4-1 inhibitors identified by the screening methods NEDD4, STUB1, CUL1 MEN1 2112/4885KMT2A 2599/4885NPC1 1703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.